Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jun 5, 2008

EPIX Earns $5.5M Milestone from GSK

  • EPIX Pharmaceuticals achieved a key milestone related to the third of three discovery programs under its collaboration with GlaxoSmithKline (GSK), triggering a $5.5 million payment.

    Using its integrated computational-medicinal chemistry approach to drug discovery, EPIX has identified three lead candidates to move forward into lead optimization in its GPCR discovery research.

    EPIX is now entitled to receive a milestone payment of $3 million and an additional $2.5 million for its overall progress in the discovery partnership with GSK. EPIX previously received two milestone payments totaling $6 million for the other two discovery programs.

    “Our in silico approach to drug discovery continues to deliver results and has allowed us to rapidly progress lead candidates into lead-optimization programs,” notes Sheila DeWitt, Ph.D., vp of discovery at EPIX.

    In December 2006, EPIX and GSK announced a worldwide, multitarget strategic collaboration to discover, develop, and market novel medicines targeting four GPCRs for the treatment of a variety of diseases. EPIX received total initial payments of $35 million, including $17.5 million through the purchase of its common stock.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »